Oliveira Jennifer L, Coon Lea M, Frederick Lori A, Hein Molly, Swanson Kenneth C, Savedra Michelle E, Porter Tavanna R, Patnaik Mrinal M, Tefferi Ayalew, Pardanani Animesh, Grebe Stefan K, Viswanatha David S, Hoyer James D
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.
Department of Hematology and Oncology, Mayo Clinic, Rochester, MN.
Am J Hematol. 2018 May 23. doi: 10.1002/ajh.25150.
Hereditary erythrocytosis is associated with high oxygen affinity hemoglobin variants (HOAs), 2,3-bisphosphoglycerate deficiency and abnormalities in EPOR and the oxygen-sensing pathway proteins PHD, HIF2α, and VHL. Our laboratory has 40 years of experience with hemoglobin disorder testing and we have characterized HOAs using varied protein and molecular techniques including functional assessment by p50 analysis. In addition, we have more recently commenced adding the assessment of clinically relevant regions of the VHL, BPGM, EPOR, EGLN1 (PHD2), and EPAS1 (HIF2A) genes in a more comprehensive hereditary erythrocytosis panel of tests. Review of our experience confirms a wide spectrum of alterations associated with erythrocytosis which we have correlated with phenotypic and clinical features. Through generic hemoglobinopathy testing we have identified 762 patients with 81 distinct HOA Hb variants (61 β, 20 α), including 12 that were first identified by our laboratory. Of the 1192 cases received for an evaluation specific for hereditary erythrocytosis, approximately 12% had reportable alterations: 85 pathogenic/likely pathogenic mutations and 58 variants of unknown significance. Many have not been previously reported. Correlation with clinical and phenotypic data supports an algorithmic approach to guide economical evaluation; although, testing is expanded if the suspected causes are negative or of uncertain significance. Clinical features are similar and range from asymptomatic to recurrent headaches, fatigue, restless legs, chest pain, exertional dyspnea and thrombotic episodes. Many patients were chronically phlebotomized with reported relief of symptoms. This article is protected by copyright. All rights reserved.
遗传性红细胞增多症与高氧亲和力血红蛋白变异体(HOAs)、2,3-二磷酸甘油酸缺乏以及促红细胞生成素受体(EPOR)和氧感应途径蛋白脯氨酰羟化酶(PHD)、缺氧诱导因子2α(HIF2α)和血管性血友病因子(VHL)的异常有关。我们实验室在血红蛋白疾病检测方面拥有40年的经验,并且我们已经使用多种蛋白质和分子技术对HOAs进行了特征分析,包括通过p50分析进行功能评估。此外,我们最近开始在更全面的遗传性红细胞增多症检测组合中增加对VHL、BPGM、EPOR、EGLN1(PHD2)和EPAS1(HIF2A)基因临床相关区域的评估。对我们经验的回顾证实了与红细胞增多症相关的广泛改变,我们已将这些改变与表型和临床特征相关联。通过常规血红蛋白病检测,我们确定了762例患者,他们携带81种不同的HOA血红蛋白变异体(61种β型,20种α型),其中12种是由我们实验室首次鉴定的。在接受遗传性红细胞增多症特异性评估的1192例病例中,约12%有可报告的改变:85个致病/可能致病突变和58个意义未明的变异体。许多此前尚未见报道。与临床和表型数据的相关性支持一种算法方法来指导经济有效的评估;不过,如果可疑病因检测结果为阴性或意义不确定,则需扩大检测范围。临床特征相似,从无症状到反复头痛、疲劳、不安腿综合征、胸痛、劳力性呼吸困难和血栓形成发作不等。许多患者长期接受放血治疗,症状有所缓解。本文受版权保护。保留所有权利。